Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.
2.

Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.

Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, Seshadri R, Pegg AE, Williams DA.

Cancer Res. 2000 Sep 15;60(18):5187-95.

3.

Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.

Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL.

Hum Gene Ther. 1999 Nov 20;10(17):2769-78.

PMID:
10584923
4.

A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents.

Jelinek J, Rafferty JA, Cmejla R, Hildinger M, Chinnasamy D, Lashford LS, Ostertag W, Margison GP, Dexter TM, Fairbairn LJ, Baum C.

Gene Ther. 1999 Aug;6(8):1489-93.

5.

F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.

Maier P, Heckmann D, Spier I, Laufs S, Zucknick M, Allgayer H, Fruehauf S, Zeller WJ, Wenz F.

Cancer Gene Ther. 2012 Nov;19(11):802-10. doi: 10.1038/cgt.2012.67. Epub 2012 Oct 5.

PMID:
23037811
6.

Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy.

Suzuki M, Sugimoto Y, Tsukahara S, Okochi E, Gottesman MM, Tsuruo T.

Clin Cancer Res. 1997 Jun;3(6):947-54.

7.

Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.

Kramer BA, Lemckert FA, Alexander IE, Gunning PW, McCowage GB.

J Gene Med. 2006 Sep;8(9):1071-85.

PMID:
16927363
8.

Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).

Maier P, Spier I, Laufs S, Veldwijk MR, Fruehauf S, Wenz F, Zeller WJ.

Gene Ther. 2010 Mar;17(3):389-99. doi: 10.1038/gt.2009.133. Epub 2009 Oct 29.

PMID:
19865182
10.

Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.

Cai S, Xu Y, Cooper RJ, Ferkowicz MJ, Hartwell JR, Pollok KE, Kelley MR.

Cancer Res. 2005 Apr 15;65(8):3319-27.

11.
12.

Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.

Jansen M, Sorg UR, Ragg S, Flasshove M, Seeber S, Williams DA, Moritz T.

Cancer Gene Ther. 2002 Sep;9(9):737-46.

13.
14.

Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.

Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA.

Cancer Res. 2008 Aug 1;68(15):6171-80. doi: 10.1158/0008-5472.CAN-08-0320.

17.
18.

Retroviral-mediated transfer and expression of the multidrug resistance protein 1 gene (MRP1) protect human hematopoietic cells from antineoplastic drugs.

Omori F, Juopperi T, Chan CK, Chang YN, Phipps S, Nanji S, Zhao Y, Stewart AK, Dubé ID.

J Hematother Stem Cell Res. 1999 Oct;8(5):503-14.

PMID:
10791901
19.

Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.

Fontes AM, Davis BM, Encell LP, Lingas K, Covas DT, Zago MA, Loeb LA, Pegg AE, Gerson SL.

Mol Cancer Ther. 2006 Jan;5(1):121-8.

20.

Genetic modification of haematopoietic cells for combined resistance to podophyllotoxins, other agents covered by MDR1-mediated efflux activity and nitrosoureas.

Baum C, Peinert S, Carpinteiro A, Eckert HG, Fairbairn LJ.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S71-4.

PMID:
10933194

Supplemental Content

Support Center